- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Elevated Hba1C During First Trimester Linked With Adverse Pregnancy Outcome
Gestational diabetes (GDM) is a common pregnancy complication associated with adverse maternal and fetal outcomes including an increased risk for type 2 diabetes and cardiovascular disease later in life in mothers and an increased risk for macrosomia and obesity in offspring. However, a recent study suggests that elevated glycated haemoglobin (HbA1c) in the first trimester (HbA1c-FT) is linked with adverse pregnancy events in non-GDM Asian Indians. The updated study findings were published in the Journal of Diabetes and its Complications on April 13, 2022.
HbA1c analysis was endorsed as a screening test for unrecognised diabetes in both the general population and in early pregnancy. A few prior studies have examined if HbA1c measured in the first trimester is useful for the early prediction of GDM. However, its significance in non-GDM individuals is understudied. Therefore, Dr John Punnose and his team conducted a study to determine the association of HbA1c-FT with adverse events among pregnant Asian Indian women without GDM.
In this retrospective cohort study, the researchers included 1618 pregnant women who delivered at a single urban tertiary care centre and had HbA1c-FT estimation between January 2011 and September 2017. They used multivariable logistic regression models to assess the association between elevated HbA1c-FT and adverse events.
Key findings of the study:
- Upon analysis, the researchers found that at a cutoff of ≥37 mmol/mol (5.5%), HbA1c-FT was associated with preterm birth at <37 gestational weeks (adjusted odds ratio (OR) 2.10).
- They observed that there was a continuum of risk for primary caesarean delivery with higher HbA1c-FT levels (adjusted OR per 5-mmol/mol (0.5%) increase in HbA1c-FT for primary caesarean delivery: 1.27).
- Upon crude analysis, they found that gestational hypertension was associated with HbA1c-FT. However, not after adjustment for confounding factors.
- They reported that HbA1c-FT was not associated with other adverse events (macrosomia, large for gestational age babies, or other neonatal complications).
The authors concluded, "Even without GDM, the results suggest an association of HbA1c-FT with preterm birth and primary caesarian delivery among Asian Indian women."
They further highlighted, "Mechanism of HbA1c-FT association with adverse events in non-GDM women is unclear".
For further information:
DOI: https://doi.org/10.1016/j.jdiacomp.2022.108187
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751